Denali Therapeutics Inc.
151 Oyster Point Boulevard
South San Francisco
About Denali Therapeutics Inc.Denali Therapeutics Inc. is a privately held biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Located in South San Francisco, Denali was founded by Drs. Marc Tessier-Lavigne, Ryan Watts, Alex Schuth and investors who share the vision that recent scientific insights in genetics, biology and translational medicine offer an unprecedented opportunity to discover and develop effective medicines for neurodegenerative disease. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include ARCH Venture Partners, F-Prime Biosciences, Flagship Ventures and the Alaska Permanent Fund.
Founder and CEO: Ryan Watts
Founder and COO: Alexander Schuth
Founder: Marc Tessier-Lavigne
CMO: Carole Ho
CFO: Steve Krognes
Please click here for Denali job opportunities.
31 articles with Denali Therapeutics Inc.
CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical TrialsCENTOGENE to conduct a targeted global identification and recruitment campaign to support Denali´s LRRK2 inhibitor program
CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation carrier Parkinson’s disease (“PD”) patients.
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that Dr. Dana Andersen has joined the company as Chief Technical and Manufacturing Officer.
Denali Therapeutics stock climbed 11 percent after the release of positive data from its Phase I clinical trial of DNL201 in Parkinson’s disease.
In March venture capital firm ShangPharma Innovations announced its plans to expand its life sciences incubator in San Francisco by 40 percent, including state-of-the-art laboratory infrastructure upgrades to its facility. That investment is paying off as the incubator is growing.
AbCellera Announces Collaboration with Denali Therapeutics to Discover New Antibodies to Treat Neurodegenerative Diseases
Collaboration uses AbCellera’s high-throughput single-cell screening capabilities to find new antibodies against a target identified by Denali linked to neurodegenerative disorders
F-star announced that its partner Denali Therapeutics (NASDAQ: DNLI) (Denali) has chosen to exercise early its option to acquire the asset-centric vehicle F-star Gamma Ltd (F-star Gamma).
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
It’s no secret that drugmakers have struggled to develop a therapeutic to treat or halt the onset of Alzheimer’s disease. Multiple drugs have failed in late-stage trials and some companies, such as Pfizer, have largely given up on the space.
Denali Therapeutics, located in South San Francisco, California, had a lot of news to share today.
Parkinson’s Institute and Clinical Center Collaborates With Denali Therapeutics to Explore New Endpoints for Clinical Studies
The Parkinson’s Institute and Clinical Center and Denali Therapeutics Inc.s announced a partnership to explore new clinical endpoints for studies in patients with Parkinson’s Disease (PD).
Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines
The agreement covers all stages of the development and manufacturing.
A look at whether big money and big deals will be in store for 2018.
Will this new buy be enough for Celgene investors?
Takeda CEO Christophe Weber is sticking to his game plan of actively hunting deals that will expand its global presence and create a stronger international profile.
12/21/2017Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.
Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson's Disease
Based on a full review of the clinical data from this ongoing study, and additional preclinical data, the FDA has removed the previously imposed partial clinical hold.
Denali Therapeutics Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Goldman Sachs & Co. LLC, Morgan Stanley and J.P. Morgan acted as joint book-running managers for the offering, and Evercore Group L.L.C. acted as lead manager for the offering.
12/12/2017A look at what three ex-Genentech employees have accomplished at Denali so far.
With the raise, the company's market valuation is currently $1.7B.
Denali plans to make a $100M IPO under the symbol DNLI.